Pfizer Repayments of Short-Term Debt decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $2.05B to $0.00.
High repayment levels indicate the firm is successfully deleveraging or rolling over short-term obligations.
This represents cash outflows used to settle short-term debt obligations, including commercial paper and other borrowing...
Standard for all firms with active treasury management; should be viewed alongside issuance levels.
financing_repayments_of_short_term_debt| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $1.00M | -$1.00M | $971.75M | $971.75M | $971.75M | $971.75M | $0.00 | $0.00 | $0.00 | $3.00M | $328.00M | $4.52B | $2.92B | $3.45B | $2.05B | $151.00M | $0.00 |
| QoQ Change | — | — | -200.0% | >999% | +0.0% | +0.0% | +0.0% | -100.0% | — | — | — | >999% | >999% | -35.4% | +18.1% | -40.7% | -92.6% | -100.0% |
| YoY Change | — | — | — | — | — | >999% | >999% | -100.0% | -100.0% | -100.0% | -99.7% | — | — | — | >999% | +524.4% | -96.7% | -100.0% |